Citius Oncology Inc expected to post a loss of 5 cents a share - Earnings Preview

Citius Oncology

07/08/2026 15:45

Citius Oncology Inc CTOR.OQ CTOR.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Cranford New Jersey-based  company is expected to report revenue of $5.831 million, according to the estimate from one analyst, based on LSEG data.
​LSEG's mean analyst estimate for Citius Oncology Inc is for a loss of 5 cents per share. 
The one available analyst rating on the shares is "buy".  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Citius Oncology Inc is $4.00, about 426.3% above its last closing price of $0.76
This summary was machine generated August 7 at 14:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)